GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today it has been developing a recombinant polyclonal antibody therapy for the treatment of COVID-19.

Read the full press release.